About: IMPACT OF GLUCOCORTICOID TREATMENT IN SARS-COV-2 INFECTION MORTALITY: A RETROSPECTIVE CONTROLLED COHORT STUDY

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: IMPACT OF GLUCOCORTICOID TREATMENT IN SARS-COV-2 INFECTION MORTALITY: A RETROSPECTIVE CONTROLLED COHORT STUDY Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	IMPACT OF GLUCOCORTICOID TREATMENT IN SARS-COV-2 INFECTION MORTALITY: A RETROSPECTIVE CONTROLLED COHORT STUDY
Creator	Alonso, Silvia Adolfo, Gustavo Alijo, Ángela Avendaño-Solá, Cristina Callejas Díaz, Alejandro Chica, Enrique Delgado Téllez De Cepeda, Laura Fernández Cruz, Ana Galán Gómez, Amy Garachana, Laura Gómez Irusta, Javier Mills Sánchez, Patricia Muñoz Gómez, Ana Payares-Herrera, Concepción Ramos Martínez, Antonio Rubio, Elena Ruiz-Antorán, Belén Sancho López, Aránzazu Soto, Centeno Torre, Ignacio
Source	MedRxiv
abstract	Objective: We aim to determine the impact of steroid use in COVID-19 pneumonia in-hospital mortality. Design: We performed a single-centre retrospective cohort study. Setting: A University hospital in Madrid, Spain, during March 2020. Participants: Patients admitted with SARS-CoV-2 pneumonia. Exposures: Patients treated with steroids were compared to patients not treated with steroids. A propensity-score for steroid treatment was developed. Different steroid regimens were also compared, and adjusted with a second propensity score. Main Outcomes and Measures: To determine the role of steroids in in-hospital mortality, univariable and multivariable analyses were performed, and adjusted including the propensity score as a covariate. Survival times were compared using a log-rank test. Results: During the study period, 463 out of 848 hospitalized patients with COVID19 pneumonia fulfilled inclusion criteria. Among them, 396 (46.7%) consecutive patients were treated with steroids and 67 patients were assigned to the control cohort. Global mortality was 15.1%. Median time to steroid treatment from symptom onset was 10 days (IQR 8 to13). In-hospital mortality was lower in patients treated with steroids than in controls (13.9% [55/396] versus 23.9% [16/67], OR 0.51 [0.27 to 0.96], p= 0.044). Steroid treatment reduced mortality by 41.8% relative to no steroid treatment (RRR 0,42 [0.048 to 0.65). Initial treatment with 1 mg/kg/day of methylprednisolone (or equivalent) versus steroid pulses was not associated with in-hospital mortality (13.5% [42/310] versus 15.1% [13/86], OR 0.880 [0.449-1.726], p=0.710). Conclusions: Our results show that survival of patients with SARS-CoV2 pneumonia is higher in patients treated with glucocorticoids than in those not treated. In-hospital mortality was not different between initial regimens of 1 mg/kg/day of methylprednisolone or equivalent and glucocorticoid pulses. These results support the use of glucocorticoids in SARS-CoV2 infection.
has issue date	2020-05-26(xsd:dateTime)
bibo:doi	10.1101/2020.05.22.20110544
has license	medrxiv
sha1sum (hex)	6da4b663b277d665282607bbeb7dc5d036bf4931
schema:url	https://doi.org/10.1101/2020.05.22.20110544
resource representing a document's title	IMPACT OF GLUCOCORTICOID TREATMENT IN SARS-COV-2 INFECTION MORTALITY: A RETROSPECTIVE CONTROLLED COHORT STUDY
resource representing a document's body	covid:6da4b663b277d665282607bbeb7dc5d036bf4931#body_text
is schema:about of	named entity 'odds ratio' named entity 'ICU' named entity 'steroid' named entity 'steroid' named entity 'hemophagocytic lymphohistiocytosis' named entity 'serum' named entity 'steroid' named entity 'steroids' named entity 'propensity score' named entity 'SARS-CoV-2' named entity 'COHORT STUDY' named entity 'SARS-COV-2' named entity 'GLUCOCORTICOID' named entity 'May 26' named entity 'preprint' named entity 'therapeutic window' named entity 'BRA' named entity 'steroid' named entity 'CC-BY-NC-ND 4.0' named entity 'ARDS' named entity 'dexamethasone' named entity 'cytokine' named entity 'D-dimer' named entity 'steroids' named entity 'steroids' named entity 'ritonavir' named entity 'steroids' named entity 'preprint' named entity 'covariate' named entity 'preprint' named entity 'evolution' named entity 'steroids' named entity 'D-dimer' named entity 'COVID' named entity 'CC-BY-NC-ND 4.0' named entity 'steroid' named entity 'medRxiv' named entity 'corticosteroid' named entity 'March 2020' named entity 'steroid' named entity 'interleukin-6' named entity 'Kaplan-Meier' named entity 'medRxiv' named entity 'inflammatory' named entity 'darunavir' named entity 'propensity scores' named entity 'medRxiv' named entity 'medRxiv' named entity 'preprint' named entity 'Cerner' named entity 'steroids' named entity 'SARS-CoV2' named entity 'statistical significance' named entity 'steroid' named entity 'preprint' named entity 'corticosteroids' named entity 'preprint' named entity 'infection' named entity 'medRxiv' named entity 'steroids' named entity 'antiinflammatory' named entity 'steroid' named entity 'steroid' named entity 'preprint' named entity 'ICU' named entity 'CC-BY-NC-ND 4.0'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software